Begoña P. Valderrama
0000-0003-0175-1263
Publication & Citation Trends
Publications
0 total
SASAN-SPARING: A phase 2 trial of sasanlimab maintenance as bladder-sparing option after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer.
Cited by 0
Semantic Scholar
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.
Cited by 0
Semantic Scholar
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study
Cited by 0
Semantic Scholar
Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.
Cited by 0
Semantic Scholar
Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.
Cited by 0
Semantic Scholar
Avelumab First-Line Maintenance (1LM) for Advanced Urothelial Carcinoma (aUC): Long-Term Outcomes from JAVELIN Bladder 100 in Patients with Low Tumor Burden
Cited by 0
Semantic Scholar
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma
Cited by 1
Semantic Scholar
Research Topics
Bladder and Urothelial Cancer Treatments
(128)
Cancer Immunotherapy and Biomarkers
(98)
Urinary and Genital Oncology Studies
(76)
Renal cell carcinoma treatment
(34)
Prostate Cancer Treatment and Research
(15)
Affiliations
Goethe University Frankfurt
Memorial Sloan Kettering Cancer Center
Radboud University Nijmegen
Inserm
Université de Versailles Saint-Quentin-en-Yvelines